Relmada Therapeutics, Inc.

Hello, and welcome to the Realmata Therapeutics 3rd Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode. After the prepared remarks, we will conduct a question and answer session. To ask a question, please press star 1. As a reminder, this conference call is being recorded and will be available for replay on the location website. I would now like to turn the call over to Tim McCarthy from LifeSci Advisors. Please go ahead, Mr. McAfee.

Good day, everyone, and thank you for joining us today.

This afternoon, Ramada issued a press release providing a business update and outlining its financial results for the three months ended September 30, 2024. Please note that certain information discussed on the call today is covered under the safe harbor provision of the Private Securities Litigation Reform Act. We caution listeners that during this call, Ramada's management team will be making forward-looking statements. Actual results could differ materially from those stated or implied by these forward-looking statements due to risks and uncertainties associated with the company's business. These forward-looking statements are qualified by the cautionary statements contained in RealMata's press release issued today and the company's SEC filings, including in the annual report on Form 10-K for the year ended December 31, 2023, and subsequent filings, including the third quarter 2024 10-Q filed after the close today. This conference call also contains time-sensitive information and is accurate only as of the date of this live broadcast, November 7, 2024. Ramada undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this conference call. With me on today's call are Ramada's CEO, Dr. Sergio Traversa, who will briefly provide a summary of recent business highlights, and Ramada's CFO, Megan Shenouda, who will provide a review of the company's Q3 financial results. After that, we will open the line for brief Q&A session. Now, I would like to hand the call over to Sergio Traversa. Sergio?